Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Valiya, SN
dc.contributor.author Bajorek, BV
dc.date.accessioned 2012-02-02T11:01:28Z
dc.date.issued 2005-12
dc.identifier.citation Journal of Pharmacy Practice and Research, 2005, 35 (4), pp. 279 - 283
dc.identifier.issn 1445-937X
dc.identifier.other C1UNSUBMIT en_US
dc.identifier.uri http://hdl.handle.net/10453/15648
dc.description.abstract Background: The benefit of warfarin for stroke prevention in non-valvular atrial fibrillation has been demonstrated in various clinical trials. Warfarin has a narrow therapeutic window and carries a significant risk of bleeding. Ximelagatran is a new oral antithrombotic with predictable plasma concentrations and excellent bioavailability. Aim: To compare the costs and benefits of ximelagatran to that of warfarin and aspirin. Method: In a preliminary cost-effectiveness analysis, the costs and clinical consequences of warfarin, aspirin and ximelagatran were compared. The principal outcome was measured in the form of an incremental cost-effectiveness ratio. A decision analysis model was constructed to map the expected outcomes of three treatment alternatives. Sensitivity analysis tested the robustness of the data. Results: Warfarin appeared to be most cost effective in this clinical setting. The incremental cost-effectiveness ratio indicated that the use of ximelagatran in preference to warfarin would cost an additional $272 000/patient/year. Likewise the use of ximelagatran in preference to aspirin would cost an additional $13 000/patient/year. Conclusion: Ximelagatran appears to be cost effective in a small group of high-risk patients. This may have implications for the development of treatment guidelines in this clinical setting.
dc.language eng
dc.title Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation
dc.type Journal Article
dc.parent Journal of Pharmacy Practice and Research
dc.journal.volume 4
dc.journal.volume 35
dc.journal.number 4 en_US
dc.publocation Australia en_US
dc.identifier.startpage 279 en_US
dc.identifier.endpage 283 en_US
dc.cauo.name GSH.Pharmacy en_US
dc.conference Verified OK en_US
dc.for 1115 Pharmacology and Pharmaceutical Sciences
dc.personcode 112624
dc.percentage 100 en_US
dc.classification.name Pharmacology and Pharmaceutical Sciences en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords NA en_US
dc.description.keywords Limb rehabilitation, Backpropagation Neural Network, surface EMG (sEMG), Virtual Reality
dc.description.keywords NA
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Graduate School of Health
pubs.organisational-group /University of Technology Sydney/Strength - Health Services and Practice Research


Files in this item

This item appears in the following Collection(s)

Show simple item record